Abstract
Pfizer's deal with the Sanford-Burnham Medical Research Institute to identify and validate new drug targets to prevent and treat insulin resistance and organ damage in obesity-related diabetes could help reverse a trend that has seen the pharma arriving late—or not at all—to the party with new targets for the indication.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
